Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H22N6.C4H6O6.2H2O |
| Molecular Weight | 448.4714 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN[C@@H]1CCN(C1)C2=CC(NCC3CC3)=NC(N)=N2
InChI
InChIKey=AZNYKQWIUUFUID-FXPVNMEJSA-N
InChI=1S/C13H22N6.C4H6O6.2H2O/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9;5-1(3(7)8)2(6)4(9)10;;/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18);1-2,5-6H,(H,7,8)(H,9,10);2*1H2/t10-;1-,2-;;/m11../s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C13H22N6 |
| Molecular Weight | 262.354 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C4H6O6 |
| Molecular Weight | 150.0868 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
PF-03893787 is potent and selective histamine H4 receptor (H4R) antagonist. It has comparable binding affinity to the human histamine H3 receptor. PF-03893787 was found to have significant affinity for the hERG channel. Novartis initiates a phase II extension trial in Atopic dermatitis. Studies exploring the utility of PF-3893787 in patients would be reported in due course, being the potential indications of asthma, pruritus, inflammatory skin diseases and pain, among others.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation. | 2016-10 |
|
| A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787. | 2013-05-01 |
|
| Is the H4 receptor a new drug target for allergies and asthma? | 2013-01-01 |
|
| Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. | 2011-11-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:12:43 GMT 2025
by
admin
on
Mon Mar 31 23:12:43 GMT 2025
|
| Record UNII |
D0DVK27O02
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2096455-87-5
Created by
admin on Mon Mar 31 23:12:43 GMT 2025 , Edited by admin on Mon Mar 31 23:12:43 GMT 2025
|
PRIMARY | |||
|
D0DVK27O02
Created by
admin on Mon Mar 31 23:12:43 GMT 2025 , Edited by admin on Mon Mar 31 23:12:43 GMT 2025
|
PRIMARY | |||
|
131634758
Created by
admin on Mon Mar 31 23:12:43 GMT 2025 , Edited by admin on Mon Mar 31 23:12:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |